The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man.

@article{Hughes1988TheEO,
  title={The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man.},
  author={Jennifer M. Hughes and Thomas R. Beck and Charles E. Rose and Robert M. Carey},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1988},
  volume={66 3},
  pages={
          518-25
        }
}
  • J. Hughes, T. Beck, +1 author R. Carey
  • Published 1988
  • Chemistry, Medicine
  • The Journal of clinical endocrinology and metabolism
We studied the actions of iv fenoldopam, a selective dopamine-1 (DA-1) receptor agonist, in 10 normal men eating a diet containing 150 meq sodium and 60 meq potassium per day. During DA-1 receptor stimulation systemic hemodynamic function did not change. Fenoldopam resulted in an increase in urine flow rate from 13 +/- 1 (+/- SE) to a peak of 17 +/- 2 mL/min (P less than 0.05) and an increase in renal plasma flow from 344 +/- 39 to 481 +/- 44 mL/min (P less than 0.05). Urinary sodium excretion… Expand
Selective Peripheral Dopamine‐1 Receptor Stimulation: Differential Responses to Sodium Loading and Depletion in Humans
TLDR
Attenuation of the DA, natriuretic response during sodium depletion suggests a direct inhibition of cellular DA, mechanisms in the renal tubule or recruitment of nondopaminergic compensatory homeostatic mechanisms within the kidney. Expand
Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
TLDR
In normal subjects, fenoldopam, a specific DA1 agonist, like DA, stimulates renal PGI2 release and RBF, suggesting an alteration of dopaminergic tone in some hypertensives that is characterized by a defect in DA1 receptor sensitivity. Expand
Intrarenal dopamine production and distribution in the rat. Physiological control of sodium excretion.
TLDR
It is demonstrated that both chronic sodium loading and acute gludopa administration stimulated renal DA production and release predominantly into the tubule lumen, where DA had a direct tubule action in the control of UNaV. Expand
Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study
TLDR
The acute administration of fenoldopam did not improve renal hemodynamics or function in patients with cirrhosis and ascites, and dopamine DA1 agonism caused further increases in norepinephrine concentration and plasma renin activity. Expand
Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension.
TLDR
Findings show that acute BP reduction with fenoldopam is associated with both a diuresis and natriuresis in severely hypertensive patients while lowering BP with nitroprusside does not predictably alter renal function and causes a moderate expansion in volume. Expand
Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodium-loaded rats.
TLDR
In summary, acute kidney-specific lipid raft disruption decreases CAV1 expression and blocks D(1)-like receptor-induced natriuresis and chronic disruption of lipid rafts orCAV1 protein expression in the kidney induces hypertension. Expand
Lack of effect of lithium on the renal response to DA1-dopamine receptor stimulation by fenoldopam in normal man.
TLDR
It is concluded that a previously described interaction between lithium and the dopamine agonist gludopa is not mediated by DA1-dopamine receptors or is confined to higher doses of lithium. Expand
Potential of dopamine A-1 agonists in the management of acute renal failure.
  • I. Singer, M. Epstein
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1998
TLDR
Results of several studies in normal and hypertensive humans, and a few studies in animal models, are consistent with the notion that DA-1 agonists may be useful in preventing or treating ARF. Expand
Renal Dopamine System: Paracrine Regulator of Sodium Homeostasis and Blood Pressure
TLDR
In experimental and human hypertension, 2 renal dopaminergic defects have been described: decreased renal generation of dopamine and a D 1 receptor-G protein coupling defect, which lead to renal sodium retention, and each may play an important role in the pathophysiology of essential hypertension. Expand
Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
TLDR
Fenoldopam mesylate improves cardiac output and lowers systemic vascular resistance with relative attenuation of pharmacodynamic effect during a 24-hour intravenous infusion. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
TLDR
The results suggest that reduced dopaminergic activity expressed at the peripheral DA-1 receptor may contribute to the pathophysiology and/or maintenance of increased blood pressure in essential hypertension and that peripheral DA -1 receptor stimulation with SKF 82526-J may be efficacious in the treatment of human essential hypertension. Expand
Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
TLDR
Dissociation of the responses to the dopamine agonists, dopamine and bromocriptine, is suggested, and indicates that a new type of dopamine receptor may inhibit aldosterone secretion. Expand
Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.
TLDR
A series of studies were undertaken to assess the effect of oral fenoldopam, a specific DA1 dopamine receptor agonist on blood pressure and renal function in patients with mild essential hypertension, with a significant, dose-related reduction in diastolic blood pressure, and increase in heart rate. Expand
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics
TLDR
It is shown that intravenous fenoldopam causes systemic arteriolar vasodilation, accompanied by renal vasODilation and increased sodium excretion, and is associated with dose‐related increases in para‐aminohippuric acid clearance. Expand
Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
TLDR
The results suggest that aldosterone production is under maximum tonic dopaminergic inhibition which can be overridden with stimulation by angiotensin II in normal man. Expand
Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390.
TLDR
The data indicate that the effects of DA to increase RBF and electrolyte excretion are the result of action on DA1 receptors, suggesting that in these experiments endogenous DA was not active. Expand
Dopaminergic suppression of angiotensin II-induced aldosterone secretion in man: differential responses during sodium loading and depletion.
TLDR
Dopamine administration was associated with an increase in plasma cortisol concentration from 90 to 150 minutes of infusion and remained suppressed with dopamine for the remainder of the dopamine infusion, and angiotensin II-induced aldosterone secretion in the sodium-depleted state. Expand
The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.
TLDR
The results show a pronounced renal vasodilator effect lasting about 2 h, consistent with marked DA1 receptor agonist activity. Expand
A new oral renal vasodilator, fenoldopam
TLDR
Findings indicate that fenoldopam is an active renal vasodilator in man and increases urine volume, free water clearance, and fractional excretion of sodium by stimulation of renal dopamine receptors. Expand
Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390.
TLDR
Data indicate that SCH 23390 is the most specific and selective antagonist of DA1 receptors thus far described and should be extremely useful in investigations of potential physiological and pathological roles of DA and in the classification of DA receptors. Expand
...
1
2
3
4
...